Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA RNA-pulsed dendritic cell vaccine in metastatic prostate cancer
NCT00004211Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 1999
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prostate-specific antigen RNA-pulsed dendritic cell vaccine in prostate cancer (PCa), sponsored by Duke University. Primary endpoint: Safety and Feasibility of PSA RNA pulsed autologous dendritic cells at 1 year. Started Jul 1999; status: completed.
02
Drugs
prostate-specific antigen RNA-pulsed dendritic cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00004211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004211.